Vertex Pharmaceuticals
$506.74Change from previous close: −3.07%Absolute change: −$16.07
At a glance
- Revenue growth
- +8.90%
- 2025 vs 2024
- Net margin
- 32.9%
- 2024: -4.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 12,001 | 11,020 | 9,869 | 8,931 | 7,574 | 6,206 | 4,163 | 3,048 | 2,489 | 1,702 |
| Cost of revenue | 5,561 | 5,161 | 4,425 | 3,608 | 2,842 | 2,381 | 2,302 | 1,826 | 1,600 | 1,258 |
| Gross profit | 6,441 | 5,859 | 5,444 | 5,323 | 4,732 | 3,825 | 1,861 | 1,222 | 889 | 444 |
| Selling, general and administrative | 1,753 | 1,464 | 1,137 | 945 | 840 | 771 | 659 | 558 | 496 | 433 |
| Research and development | 4,043 | 8,259 | 3,690 | 2,656 | — | — | — | — | — | — |
| Operating income | 4,687 | 4,395 | 4,308 | 4,378 | 3,892 | 3,054 | 1,202 | 664 | 393 | 11.2 |
| EBIT | 4,687 | 4,395 | 4,308 | 4,378 | 3,892 | 3,054 | 1,202 | 664 | 393 | 11.2 |
| EBITDA | 4,866 | 4,577 | 4,477 | 4,527 | 4,018 | 3,164 | 1,309 | 736 | 454 | 72.6 |
| Interest expense | 13.3 | 30.6 | 44.1 | 54.8 | 61.5 | 58.2 | 58.5 | 72.5 | 69.3 | 81.4 |
| Pre-tax income | 4,643 | 249 | 4,380 | 4,232 | 2,730 | 3,117 | 1,395 | 600 | -15.7 | -67.4 |
| Income tax | 690 | 784 | 760 | 910 | 388 | 405 | 218 | -1,487 | -107 | 16.7 |
| Net income | 3,953 | -536 | 3,620 | 3,322 | 2,342 | 2,712 | 1,177 | 2,097 | 263 | -112 |
| Net income to common shareholders | 3,953 | -536 | 3,620 | 3,322 | 2,342 | 2,712 | 1,177 | 2,096 | 263 | -112 |
| Basic EPS | 15.46 | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 | 8.24 | 1.06 | -0.46 |
| Diluted EPS | 15.32 | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 | 1.04 | -0.46 |
| Average shares (basic) | 256 | 258 | 258 | 256 | 258 | 260 | 257 | 254 | 249 | 245 |
| Average shares (diluted) | 258 | 258 | 261 | 259 | 260 | 263 | 261 | 259 | 253 | 245 |